Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Neuren Pharmaceuticals Limited ( (AU:NEU) ) has provided an update.
Neuren Pharmaceuticals Limited has announced the quotation of 150,000 fully paid ordinary securities on the Australian Securities Exchange (ASX), effective November 25, 2025. This move is part of the company’s strategy to enhance its capital structure and potentially improve market liquidity, which could positively impact its operations and industry positioning.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$21.20 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurological disorders. The company is known for its work on treatments for conditions such as Rett syndrome and Fragile X syndrome, targeting significant unmet medical needs in the market.
YTD Price Performance: 45.20%
Average Trading Volume: 523,903
Technical Sentiment Signal: Buy
Current Market Cap: A$2.3B
For a thorough assessment of NEU stock, go to TipRanks’ Stock Analysis page.